Volume 18 (2020): Issue 3.5 (Mar 2020): Abstracts from the NCCN 2020 Annual Conference

in Journal of the National Comprehensive Cancer Network
Online ISSN:
1540-1413
Print ISSN:
1540-1405
Cover Journal of the National Comprehensive Cancer Network

 

These abstracts were accepted for the NCCN 2020 Annual Conference; however, they could not be presented because the conference was postponed due to the COVID 19 virus.

Young Investigator Awards
Best Practices in Implementation and Use of Clinical Practice Guidelines
BPI20-007: Evaluation of Guideline Adherence in Colorectal Cancer Management in a Private Clinic, Lima – Peru
BPI20-008: Pilot Testing of InheRET™, an Online Tool to Facilitate NCCN Guideline®-Compliant Referrals for Cancer Genetic Counseling and Increase Access to Care
BPI20-009: Impact of Preoperative Biliary Drainage on Postoperative Outcome for Obstructive Jaundice Patients
BPI20-010: Federally Qualified Health Centers Use of Nebraska Tobacco Quitline
BPI20-011: Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens
BPI20-012: Relative Risk of Various Endocrinopathies Associated With the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis
BPI20-013: A Systematic Review and Meta-Analysis on Mucocutaneous Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma
BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50
BPI20-015: Safety and Financial Analysis of Outpatient Dose-Adjusted EPOCH for B-cell Lymphoma at a Tertiary Comprehensive Cancer Center
BPI20-016: Comparative Study Between the Clinical Effect of Palonosetron and Granisetron as Antiemetic Therapy for Patients Receiving Highly Emetogenic Chemotherapy Regimens
BPI20-017: Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R model, 4R = Right Information / Care / Patient / Time
BPI20-018: Direction of Developing Cancer Survivorship Guidelines in Japan: An Expert Panel’s Consensus
BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
BPI20-020: Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making
BPI20-021: Metastatic Renal Cell Carcinoma and Immunotherapy, Experience in a Third Level Hospital in Mexico City
BPI20-022: Use of Cyclin Dependent Kinase 4/6 Inhibitors in Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer. Experience in a Third Level Hospital in Mexico City
BPI20-023: International Adaptation of the Resource-Stratified NCCN Frameworks for Breast, Cervical and Rectal Cancers in Bolivia
BPI20-024: Targeted Drug Delivery (TDD) for Cancer-Related Pain: Emerging Evidence
BPI20-025: Aligning Genetic Panel Utilization With Clinical Practice Guidelines Through Education
Bioinformatics/Information Technology Sciences
Clinical Oncology
CLO20-028: Clinical Utility of Encyclopedic Tumor Analysis to Treat Breast Cancer Patients who have Failed Standard of Care Treatments
CLO20-029: The Prognostic and Predictive Significance of Joint İnvestigation of Tumor Marker CA 15-3 and Vitamin D in Breast Cancer Patients
CLO20-030: Sex-Based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma
CLO20-031: Radiotherapy-Induced Malignancies in Breast Cancer Patients With Pathogenic Germline Variants TP53 in an R337H-Mutation Enriched Cohort
CLO20-032: A Founder CHEK2 Pathogenic Variant in Association With Kidney Cancer
CLO20-033: A Study of Pathological Characteristics of Malignant Cribriform Prostatic Lesions
CLO20-034: First U.S. Prospective Evaluation of Performance of 64Cu DOTATATE PET/CT in Somatostatin Expressing Neuroendocrine Tumors
CLO20-035: Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma
CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy
CLO20-037: Time is On Our Side: Concomitant Needle Biopsy and Wire-Free Localization of Axillary Lymph Nodes May Decrease Redundant Preoperative Needle Localization in BI-RADS 5, 6 Breast Cancer Patients
CLO20-038: Data From Electronic Prior Authorization Supports Real-World Evidence Generation: Contemporary Changes in the Treatment of aNSCLC
CLO20-039: Patient (pt)-Reported Outcomes (PRO) in Patients With HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups
CLO20-040: Factors Influencing Survival of Patients Treated for Spinal Metastases at a Regional Cancer Center in Appalachia
CLO20-041: Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy
CLO20-042: The HER2 FISH Ratio is a Predictor of Pathologic Complete Response Among Patients With HER2+ Breast Cancer Receiving Neoadjuvant Anti-HER2 Doublet Therapy Without Chemotherapy
CLO20-044: Laparoscopic Microwave Ablation for the Treatment of Primary and Metastatic Liver Malignancies
CLO20-045: Initial Experience of Robotic Assisted Colorectal Surgery in a Community Hospital
CLO20-046: National Cancer Institute Experience With Generic Anastrozole (Anastrodex, Hikma) in Newly Diagnosed Postmenopausal Female Egyptian Patients With Low Burden Visceral Metastatic Breast Cancer
CLO20-047: Impact of Treating Physician on Late Treatment Related Morbidity – a Secondary Analysis of a Phase III Randomized Controlled Study in Localized Prostate Cancer
CLO20-048: Role of TUBB3 Gene Expression in Early and Advanced Breast Cancer Stage Formulation
CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan
CLO20-050: Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer
CLO20-051: LYMPHA: Eliminating the Burden of Lymphedema in Cancer Patients Requiring Nodal Dissections. A Pilot Study
CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers
CLO20-053: Plinabulin, a Potent Inducer of Haptoglobin Production for the Prevention of Tissue Iron Overload in Patients Receiving Blood Transfusions Chronically
CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis
CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC)
CLO20-056: Real-Life Experience of Treatment With Anti-Programmed Cell Death-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) Antibodies in Patients With Non-Small Cells Lung Cancer (NSCLC)
CLO20-057: A Meta-Analysis on Gastrointestinal (GI) and Hepatic Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma
CLO20-058: Characteristics of Gynecological Anamnesis and its Prognostic Role in Azerbaijani Women With Breast Cancer
CLO20-059: Comparison of a Single Dose Immediate Instillation of Mitomycin C 20mg Versus 40mg in Prevention of Tumour Recurrence After Resection of Non Muscle Invasive Bladder Cancer
CLO20-060: Factors Associated with the Uptake of Adjuvant Pertuzumab in Patients with Stage I-III HER2-positive Breast Cancer: The University of Colorado Cancer Center Experience
CLO20-061: A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma
CLO20-062: Comparative Efficacy of Elotozumab With Panobinostat and Ixazomib in Multiple Myeloma; A Meta-Analysis
CLO20-063: Late Dosing of Leuprolide and Testosterone Levels >20NG/DL in Prostate Cancer Patients
CLO20-064: A Case Series of Ectopic Cushing Syndrome in Atypical Lung Carcinoid
CLO20-066: Comparative Efficacy, Safety and Acceptability of Single-Agent Poly (ADP-ribose) Polymerase (PARP) Inhibitors in BRCA Mutated HER2-Negative Metastatic or Advanced Breast Cancer: A Network Meta-Analysis
CLO20-067: Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study
CLO20-068: Incidence and Potential Predictors of Thromboembolic Events in Epithelial Ovarian Carcinoma Patients During Perioperative Period
CLO20-069: Evaluation and analysis of postoperative complications after primary cytoreduction for 47 cases of advanced epithelial ovarian cancer at stage IIIc and IV RUNNING HEAD (maximum 40 characters): Complications after primary cytoreduction in ovarian cancer
Correlative/Genomic
Epidemiology/Risks/Prevention
Outcomes and Health Services Research
HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience
HSR20-077: Determinants of Time to Treatment Initiation in Metastatic Cancers
HSR20-078: Cancer Patients and Family Caregivers as a Unit of Care
HSR20-079: Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study
HSR20-081: The Direct Referral Unit: Clinical Outcomes and Experience With a Specialized Urgent Care Center for Oncology Patients
HSR20-082: Use of the NCCN Distress Thermometer to Identify and Address Distress During a Telemedicine Visit With Rural Head and Neck Cancer Survivors
HSR20-083: Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the U.S.
HSR20-084: Real-World Adherence and Persistence of ALK Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
HSR20-085: Real-World Study of Factors Associated With Breast Conserving Surgery for Females Diagnosed With Early Stage Breast Cancer
HSR20-086: Concurrent Chemoradiation Treatment Patterns for Stage III Non-Small Cell Lung Cancer in Veterans
HSR20-087: Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List
HSR20-088: Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
HSR20-089: Association of Patient Clinico-Genomic Characteristics With Tumor Mutational Burden in Small Cell Lung Cancer: An Observational Study
HSR20-090: Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review
HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia
HSR20-092: “Write to Recover”: The Impact of Group Led Creative Writing on Physical Health Outcomes in Cancer Patients
HSR20-093: Psychosocial Support in Older Patients With Metastatic Breast Cancer (MBC) Treated at Community Centers
HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer
HSR20-095: Progression-Free Survival, Overall Survival, and Tumor Response for Patients Diagnosed With Small Cell Lung Cancer Who Received First-Line Systemic Therapy
HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
HSR20-097: Granulocyte Stimulating Colony Factor Use, Characteristics and Treatment Patterns in the United States: An Updated Analysis by the Biologics and Biosimilars Collective Intelligence Consortium
HSR20-098: A Systematic Literature Review of First-Line (1L) Treatments for Patients With MGMT (O-6-Methylguanine-DNA Methyl Transferase) Methylated and Unmethylated Glioblastoma Multiforme (GBM)
HSR20-099: Cost Comparison of PARP Inhibitors in Women With Ovarian Cancer (OC) in the US HealthCare Market
HSR20-100: Results From a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization
HSR20-101: Real-World Chemoradiotherapy Use Among Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Retrospective Observational Study
HSR20-102: Quality Outcomes in Colon Cancer
HSR20-103: Years of Potential Life Lost Due to Cervical and Uterine Cancer Deaths in the United States, 2000-2016
HSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study
HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network
HSR20-106: Quantifying Patient Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
HSR20-107: Health-Related Quality of Life and Treatment Satisfaction in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Compared to a Reference Group on Other CLL Treatments in a Real-World US Cross-Sectional Study
HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments
HSR20-109: Using Promotoras in a US-Mexico Hispanic Border Community to Provide Palliative Care
HSR20-110: The Promotion of Exercise Oncology as a Standard Part of Clinical Practice
HSR20-111: Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis
HSR20-112: Quantifying Caregiver Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
HSR20-113: Diabetes Complications and Risks of Breast Cancer Recurrence Among Older Women
HSR20-114: Impact of Social Determinants of Health on Unplanned Acute Care Service Utilization for Patients With Hematologic Malignancies
Pre-Clinical Oncology
Quality Improvement
QIM20-119: The Efficacy of Cost-Effective Fixed Dose of Rasburicase Compared to Weight-Based Dose in Treatment and Prevention of Tumor Lysis Syndrome (TLS)
QIM20-120: Financial Toxicity: Building a Patient Centered Program
QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines
QIM20-122: Use of Supportive and Palliative Care Indicators Tool in Cancer Patients: A Validity Study
QIM20-123: Utilization of a Distress Screening Tool in an Inpatient Hematopoietic Stem Cell Transplant Unit
QIM20-124: Retrospective Evaluation of VEGF Inhibitor-Associated Hypertension at a Community Cancer Center
QIM20-125: OBESE: Oncologist Based Emphasis on Survivor Education-Physician Driven Weight Loss Counseling and Outcomes in TNBC
QIM20-126: Prehabilitation Model of Care for the Patient with Breast Cancer
QIM20-127: A Team-Based Model to Promoting Hospice Utilization in High Risk Oncology Patients Through Individual Care Plan Development
QIM20-128: Baseline Assessment of Oncology Providers’ Quality Improvement Knowledge in a Multi-Institutional Breast Cancer Quality Improvement Collaborative
QIM20-129: Are You Ready? Assessing Readiness to Implement Quality Improvement in Hospitals Participating in a Breast Cancer Collaborative
QIM20-130: An Immediate Care Center for Oncology Patients “Symptom Management Doesn’t Require the Emergency Department”
QIM20-131: Fertility Preservation Discussion in Young Adults With Cancer: How Often are We Documenting?
QIM20-132: A Tool Preparing Patients with Stage III Non-Small Cell Lung Cancer for Shared Decision-Making: Validating Acceptability and Usability
QIM20-133: Rehabilitation of the Amyloidosis Patient
QIM20-134: Genetic Testing for At-Risk Patients With Colorectal and/or Pancreatic Cancer at Our Institution, a Quality Improvement Project
QIM20-135: Lifeline for Oncology Patients - Telephone Triage
QIM20-136: Integration of Tobacco Treatment Into Cancer Care at Stanford Health Care
  • Collapse
  • Expand